005500.KS
Samjin Pharmaceutical Co Ltd
Price:  
20,400 
KRW
Volume:  
45,268
Korea, Republic of | Pharmaceuticals

005500.KS WACC - Weighted Average Cost of Capital

The WACC of Samjin Pharmaceutical Co Ltd (005500.KS) is 6.9%.

The Cost of Equity of Samjin Pharmaceutical Co Ltd (005500.KS) is 8.2%.
The Cost of Debt of Samjin Pharmaceutical Co Ltd (005500.KS) is 4.5%.

RangeSelected
Cost of equity7.0% - 9.4%8.2%
Tax rate14.3% - 16.5%15.4%
Cost of debt4.0% - 5.0%4.5%
WACC5.9% - 7.9%6.9%
WACC

005500.KS WACC calculation

CategoryLowHigh
Long-term bond rate3.1%3.6%
Equity market risk premium5.8%6.8%
Adjusted beta0.670.78
Additional risk adjustments0.0%0.5%
Cost of equity7.0%9.4%
Tax rate14.3%16.5%
Debt/Equity ratio
0.430.43
Cost of debt4.0%5.0%
After-tax WACC5.9%7.9%
Selected WACC6.9%

005500.KS's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for 005500.KS:

cost_of_equity (8.20%) = risk_free_rate (3.35%) + equity_risk_premium (6.30%) * adjusted_beta (0.67) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.